Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.4 USD | -0.89% | +3.14% | -13.43% |
Financials (USD)
Sales 2024 * | 513M | Sales 2025 * | 619M | Capitalization | 3.44B |
---|---|---|---|---|---|
Net income 2024 * | -553M | Net income 2025 * | -474M | EV / Sales 2024 * | 6.25 x |
Net cash position 2024 * | 236M | Net cash position 2025 * | 301M | EV / Sales 2025 * | 5.07 x |
P/E ratio 2024 * |
-6.34
x | P/E ratio 2025 * |
-7.78
x | Employees | 1,276 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.55% |
Latest transcript on Ultragenyx Pharmaceutical Inc.
1 day | -0.89% | ||
1 week | +3.14% | ||
Current month | +3.14% | ||
1 month | +0.44% | ||
3 months | -18.07% | ||
6 months | +2.32% | ||
Current year | -13.43% |
Managers | Title | Age | Since |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 23-10-15 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 17-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 17-04-05 |
Emil Kakkis
FOU | Founder | 63 | 10-04-21 |
Daniel Welch
CHM | Chairman | 66 | 15-04-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.21% | 1 M€ | +0.84% | - | |
0.82% | 4 M€ | +20.15% | ||
0.43% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 41.4 | -0.89% | 373,401 |
24-06-06 | 41.77 | +0.77% | 935,376 |
24-06-05 | 41.45 | +1.30% | 621,988 |
24-06-04 | 40.92 | -0.51% | 645,976 |
24-06-03 | 41.13 | +2.47% | 889,598 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.43% | 3.44B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.15% | 22.78B | |
-10.46% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- RARE Stock